Skip to main content
. 2016 Aug 1;29(4):346–361. doi: 10.1089/jamp.2015.1255

FIG. 1.

FIG. 1.

OCS exacerbation incidences for individual studies of ICS/LABA combinations. ICS/LABA OCS exacerbation rates are for studies 1 and 2, and in the individual studies as reported in the Cochrane meta-analyses by Lasserson et al.(32) Ducharme et al.,(22) and Chauhan and Ducharme.(33) BDP, beclometasone; BUD, budesonide; FLN, flunisolide; FORM, formoterol; FP, fluticasone propionate; SAL, salmeterol.